Global access disparity: difference between revisions
Diff·revision 15 → 16·17:21, 31 Jul 2025
Difference between revision 15 and revision 16 of Global access disparity. 7 lines changed; the page grew by 767 bytes.
| Revision 15 — 12:37, 12 Jul 2025 FigureFerdinand (talk) ce per PP:MOS 3,508 bytes ±0 | Revision 16 — 17:21, 31 Jul 2025 TesamorelinTeg (talk) add the manufacturer assistance programme with its eligibility criterion 4,275 bytes +767 | ||
|---|---|---|---|
| 27 | The combination produces a pattern in which a person's access depends principally on where they live and what insurance they hold.{{r|who_obesity}} | 27 | The combination produces a pattern in which a person's access depends principally on where they live and what insurance they hold.{{r|who_obesity}} |
| 28 | 28 | ||
| + | 29 | == Consequences and framing == | |
| + | 30 | One documented consequence is the growth of supply outside licensed channels, which carries the identity, content, sterility and provenance uncertainties this wiki documents throughout. See [[Peptide harm reduction]] and [[Grey market]].{{r|reports}} | |
| + | 31 | ||
| + | 32 | This article describes a pattern and its drivers. It does not argue for a policy: the question of what ought to be done about access is a political one, on which this wiki takes no position, and the neutrality tag reflects a live discussion about whether the framing here achieves that.{{r|who_obesity}} | |
| + | 33 | ||
| 29 | == References == | 34 | == References == |
| 30 | {{reflist}} | 35 | {{reflist}} |
| ⋮ | ⋮ | ||
| 33 | <ref name="kyle2021">Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." ''Nursing Clinics of North America'' 56(4):635–645 (2021). PMID 34749900.</ref> | 38 | <ref name="kyle2021">Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." ''Nursing Clinics of North America'' 56(4):635–645 (2021). PMID 34749900.</ref> |
| 34 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 39 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 40 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 35 | 41 | ||
| 36 | == See also == | 42 | == See also == |
| ⋮ | ⋮ | ||
| 39 | * [[Peptide harm reduction]] | 45 | * [[Peptide harm reduction]] |
| 40 | * [[Grey market]] | 46 | * [[Grey market]] |
| + | 47 | * [[Regulatory status by jurisdiction]] | |
| 41 | 48 | ||
| 42 | {{DEFAULTSORT:Global access disparity}} | 49 | {{DEFAULTSORT:Global access disparity}} |